VYNE Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
YARW$15.79+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31 | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $24,027 | $19,926 |
| Investment in marketable securities (Note 6) | 4,981 | 41,590 |
| Prepaid and other current assets | 1,002 | 2,921 |
| Total Current Assets | 30,010 | 64,437 |
| Non-current Assets: | ||
| Property and equipment, net (Note 7) | 90 | 113 |
| Operating lease right of use assets (Note 9) | — | 93 |
| Non-current prepaid expenses and other assets | 60 | 2,262 |
| Total Non-current Assets | 150 | 2,468 |
| Total Assets | $30,160 | $66,905 |
| Liabilities and Shareholders’ Equity | ||
| Current Liabilities: | ||
| Trade payables | $1,041 | $2,707 |
| Accrued expenses (Note 8) | 941 | 9,272 |
| Employee-related obligations | 413 | 1,428 |
| Operating lease liabilities (Note 9) | — | 99 |
| Other current liabilities | — | 1,313 |
| Total Current Liabilities | 2,395 | 14,819 |
| Total Liabilities | 2,395 | 14,819 |
| Commitments and Contingencies (Note 11) | ||
| Shareholders' Equity: | ||
| Preferred stock: $0.0001 par value; 20,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock: $0.0001 par value; 150,000,000 shares authorized at December 31, 2025 and December 31, 2024; 33,323,171 and 14,830,013 shares issued and outstanding at December 31, 2025 and 2024, respectively | 3 | 1 |
| Additional paid-in capital | 785,413 | 783,235 |
| Accumulated other comprehensive income | 2 | 20 |
| Accumulated deficit | (757,653) | (731,170) |
| Total Shareholders' Equity | 27,765 | 52,086 |
| Total Liabilities and Shareholders’ Equity | $30,160 | $66,905 |
F - 2
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.